Imprimis NJOF, LLC, Ledgewood, NJ
Is Imprimis NJOF, LLC an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Imprimis NJOF, LLC in Ledgewood, NJ, first registered Nov 12, 2016 and most recently registered Nov 26, 2025. FDA lists its last inspection as Aug 18, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Ledgewood, NJ
- Initial registration
- Nov 12, 2016
- Most recent registration
- Nov 26, 2025
- Last inspection
- Aug 18, 2026
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Open
- Intends to compound sterile drugs from bulk substances
- Yes
- Earlier inspections
- FDA notes that an earlier inspection led to a Form 483, warning letter or other action
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Imprimis NJOF, LLC, Ledgewood, NJ, a 503B facility, with 4 listed actions, including 3 Form 483s and 1 warning letter (2019 to 2026).
| Document | |||
|---|---|---|---|
| Aug 18, 2026 | Form 483 | 483 Issued 08/18/2026 | fda.gov |
| Apr 3, 2024 | Form 483 | 483 Issued 04/03/2024 | FDA copy (archived) |
| Jan 29, 2021 | Form 483 | 483 Issued 01/29/2021 | FDA copy (archived) |
| Jun 7, 2019 | Warning letter | Warning Letter (06/07/2019) | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Imprimis NJOF, LLC, Ledgewood, NJ (FEI number 3013024146), matched to this page by exact name, city and state. It lists 3 inspections: 3 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Apr 3, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3013024146 | 1231238 |
| Jan 29, 2021 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3013024146 | 1135834 |
| Jul 10, 2017 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3013024146 | 1024871 |
Form 483s FDA has published for this site
- Aug 18, 2026: Form 483 to Imprimis NJOF, LLC, published Oct 6, 2026. fda.gov
- Apr 3, 2024: Form 483 to Imprimis NJOF, LLC, published Aug 6, 2024. fda.gov
- Jan 29, 2021: Form 483 to Imprimis NJOF, LLC, published Aug 13, 2021. fda.gov
- Oct 24, 2018: Form 483 to Imprimis NJOF, LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 11 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Apr 24, 2017: 11 observations
- Firm on the cover
- lmprimis NJOF, LLC, 1705 Roule 46 West, suite 68, Outsourcing Facili1y Ledgewood, NJ 07852-9720
- FEI number
- 3013024146
- FDA district office on the cover
- 10 Waterview Blvd., 3"'. Floor Parsippany, NJ 07054
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
a. The following batches of ophthalmic sterile drug products that were manufactured, released, and distributed to the market were not environmentally monitored for non-viable and viable airborne particles counts. During these manufacturing operations the <Redacted B4> and the <Redacted B4> were not operational. Additionally, the media fills that were produced to support .the sterile manufacturing operations of the below lots were also not environmentally monitored for non-viable and viable particle counts.
Specifically,
Product
Lot Number
Prednisolone (l.0%) / Garifloxacin (0.5%) / Nepafenac (0.1 %)(PGN) -Droppers
JAN007 and FEB002
Triamcinolone (l 5mg/mL)/Moxifloxacin HCI (l mglmL) (TM)-vials for injection
JAN008, JAN009, JAN010, JAN017, JAN0l8, JAN009, and JAN026.
Triamcinolone (15mg/mL)/Moxifloxacin HCI (I mg/mL)/ Vancomycin (IO mg/ml) (TMV)-vials for injection
JAN021, JAN022, JAN023, FEB006, FEB007, and FEB008
Media Fills
JANOOl, JAN002, JAN003, JAN004, JAN005, JAN006, and JAN025 ...
Observation 2
. ... Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate ·validation of the sterilization process.
Specifically, the smoke study of the ISO 5 laminar air flow hood was either not provided or lacked critical activities to demonstrate that the HEPA filtered air supply can maintain aseptic conditions. For example:
a.
The initial visualization of the unidirectional air flow (smoke study) to support the sterile filling operations in the lSO 5 <Redacted B4> laminar air flow hood during January and February 2017 was not found or provided during the inspection.
b. The air flow pattern visualization (smoke study) conducted on <Redacte d B4> failed to include cri tical activities, such as product filling, manipulation and actions whe n the <R edacted B4> is present wi th <Redacted B4> operators in the laminar air flow hood. The smoke study was conduct ed with < Redacted B4> p resent without the <Redacted B4> that holds the bulk product while no pr
oduct filling occurred . This smoke study also failed to demonstrate a continued pattern of unidirectional ai r flow. The video lasted <Redacted B4>.
Observation 3
Written procedures for cleaning and maintenance fail to include description in sufficient detail of methods, equipment and materials used.
Specifically, cleaning procedure EQU-UMR-NJR-007, Cleaning, Disinfection, and Decontamination of Clean Rooms and Equipment, fails to describe in sufficient detail the cleaning techniques and necessary steps to clean and disinfect the laminar air flow hood (ISO 5), used for filling sterile drug products. Additionally, this SOP also fails to describe the method used to clean various fixtures in the ISO 7 filling room such as the plastic curtain, doors, and piping located on the wall.
In addition, the effectiveness of the sanitization procedures have not been demonstrated through surface samples before and after cleaning and disinfection of the ISO 7 and laminar air flow hood (ISO 5) areas.
MPLEMENT. CORRECTIVE ACTIOll I» RESP()t.ISE TOAN OBSERVATION, YOU MAY OISCUSS THE OBJECTION OR ACTION WITH THE FDA REPRESEflTATIVE(S) OURJNG THE INSPECTION OR SUBMIT THIS INFORW. TION TO FDA AT Tl-IE A00R£SS ABOVE. IF YOU HAVE ANY OUESTIOllS, Pl.EASE CONTACT FDA AT THE PHONE NUMBER ANO AOORESS ABOVE.
OURING AN INSPECTION OF YOUR FIRM WE OBSERVED:
Observation 4
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch bas been already distributed.
Specifically, thorough investigations for the following customer complaints were not conducted and corrective actions were not implemented or documented.
a.
On 04/04/2017, a consumer complaint reported the presence of black/grey particles in Triamcinolone (15 mg/mL)/Moxifloxacin HCI (1 mg/mL), lot numbers JAN026 and FEB011 Lot JAN026 was released and commercially distributed to approximately <Redacted B4> customers without environmental monitoring of non-viable and viable airborne particle counts during the filling operation because the <Redacted B4> and the <Redacted B4> were not operational. Lot FEBO I I was released and commercially distributed to approximately <Redacted B4> customers. The retain samples for both lots were not evaluated to determine if they were contaminated with particles. The investigation into Lot JAN026 was not extended to other batches that were also processed without non-viable and viable airborne particle monitoring. The black/grey particles were not analyzed by a laboratory to determine their identity. ...
Observation 5
There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess.
Specifically, there is no establisbed procedure that details how to conduct the <Redacted B4> test for Moxifloxacin 5 rng/mL (0.5%) Injectable as well as what equipment and materials are needed for the test. In addition, the gauge of the <Redacted B4> used to perform this <Redacted B4> test is not calibrated and there is no established <Redacted B4> calibration procedure.
Observation 6
Production personnel were not practicing good sanitation and health habits.
Specifically, on 04/26/2017, during the filling operation of Prednisolone (l.0%)/Gatifloxacin (0.$%)/Nepafenac (0.1 %} -Droppers lot APR024 we observed two occasions when the sterile operator's band passed a bag and a tray from the
ISO 7 to the ISO 5 area without spraying their gloved hands with sterile <Redacted B4>
Observation 7
Examination of a lot of a component, drug product container or closures liable to contamination with extraneous adulterant is deficiently examined against established specifications for such contamination.
Specifically, there is no assurance that the incoming plastic bottles sterilized by <Redacted B4> and used for filling the following finished drug products are free of <Redacted B4> residue. Neither Imprimis nor the bottle supplier perform testing or have documentation to show that they are free of residue.
Prednisolone (1.0%)/Gatifloxacin (0.5%)/Nepafenac (0.1%)-Droppers
Prednisolooe {I .0%)/Gatifloxacin (0.5%)-Droppers
Prednisolooe (1.0%)/Nepafenac (0.1%) -Droppers
MPLEMENT, CORRECTIVE ACTION IN RESPONSE TO AN OBSERVATION, YOU MAY OISCUSS THE OBJECTION OR ACTIOI~ WITH THE FDA REPRESENTATIVE(S) OURJNG THE INSPECTION ORSUBl.'JT THIS IWFORMATION TO FDA AT THE ADDRESS ABOVE. IF YOU HAVE ANY QUESTIONS. PLEASE CONTACT FOAAT THE PHONE NUMBER ANO ADDRESS ABOVE.
(>U!~ING AN INSPECTION OF YOUR FIRM WE OBSERVED:
Observation 8
The identity of each component of a drug product is not verified by conducting at least one test to verify the identity, using specific identity tests if they exist.
Specifically, the following lots of API were used to manufacture sterile drug products without having a certificate of analysis from the supplier and their identification was not verified by conducting at least one test.
a. Vancomycin Hydrochloride, lot number (15) @JJ used to manufacture the validation batch Triamcinolone (15 mg/mL)/Moxifloxacin HCL ( 1 mglmL)/Vancomycin (l 0 rng/mL) Injection lot# JAN02 l. This finished sterile drug product was commercially distributed in 02/2017.
b. Vancomycin Hydrochloride, lot number <Redacted B4> used for the manufacture of Triamcinolone (15 mg/mL)/Moxifloxacin HCL (1 mg/mL)/Vancomycin (10 mg/ml) lot numbers JAN022, JAN023, FEB006, FEB007, and FEB008. These finished drug products were commercially distributed throughout February and March 2017.
Observation 9
Adequate lab facilities for testing and approval or rejection of drug products are not available to the quality control unit.
Specifically, contract laboratory facilities have not been audited or qualified to determine their adequacy for testing of drug products and media fills:
a.
There are no agreements or procedures in place with any of the contract laboratories (chemical and microbiological) to inform Imprirnis about issues that occur during laboratory testing such as deviations and out of specification (OOS) results.
b. There is no assurance that the contract laboratory used for the sterility and endotoxin testing for Triamcinolone (15 mg/mL)/Moxifloxacin HCI (1 mg/mL)/Vancomycin ( 10 mg/mL) Injectable lot numbers JAN021 and FEBOI 4, and endotoxin testing for Prednisolone (1.0%)/Gatifloxacin (0.5%)/Nepafenac (O.l %) lot number APR024 has the capability to perform the required testing in an accurate, precise, and reliable way.
c. ...
Observation 10
Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically, the number of finished product samples taken per batch is dictated by the contract laboratory. There is no Imprimis procedure or sampling plan that is used to determine if a representative quantity of drug product was taken. The following sterile drug products were involved in a customer complaint where a patient developed endophthalmitis and Staphylococcus epidermidis was identified by a hospital clinical laboratory.
a. Triamcinolone (15 mg/mL)/Moxifloxacin HCl (1 mg/mL) Injectable lot JANOI9, commercially released
to the market to approximately <R edacted B4> customers during 2017 bad a batch size of approx i m ately <Re dacted B4> vials. The sample size for chemical analysis (p otency) was <Redacted B4> vials and the samp le size for sterility a nd endotoxin testing was <Redacted B4> vials <Redacted B4> was analyzed for endotoxin testing.
b. ...
Observation 11
Establishment of the reliability of the container closure supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.
Specifically, the suppliers of the following container closure systems have not been qualified or audited. Jn addition, there has not been any testing conducted of these containers and closures to demonstrate reliability of the supplier's COA.
a. The supplier that provides the 2 ml amber vials and 13 mm grey stoppers
b. The supplier that provides the plastic bottles and < Redacted B 4>
OBSERVATJON 12
The quality control unit lacks the responsibility and authority to approve or reject all packaging material.
Specifically, the quality unit failed to identify discrepancies in the sterilization method of the <Redacted B4> (the <Redacted B4>, lot numbers <Redacted B4> and <Redacted B4> used for sterile drug products containing Prednisolone. The label indicates sterilization by <Redacted B4>; however, during the inspection, the supplier stated that the sterilization method was actually <Redacted B4> ...
Linked 483s whose text is not shown
- Aug 18, 2026: FDA document 195190: its numbered observations could not be read reliably from the PDF text.
- Apr 3, 2024: FDA document 180618: the PDF is a scanned image with no readable text.
- Jan 29, 2021: FDA document 151431: its numbered observations could not be read reliably from the PDF text.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Imprimis NJOF, LLC). That is not a finding beyond this index’s search.
The Imprimis NJOF, LLC pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.